High Ki67 expression is an independent good prognostic marker in colorectal cancer. The study analyzed 1800 colorectal cancer specimens and found that tumors with high Ki67 expression (>25% of cells staining positive) were associated with improved patient survival outcomes. While most studies find high Ki67 expression correlates with poorer prognosis in other cancers, this study and others have found the opposite relationship in colorectal cancer. The reasons for this difference are unclear. The results suggest patients with low Ki67 expression CRC tumors may benefit most from adjuvant chemotherapy.
various cutaneous lymphomas though having low incidence but need to be diagnosed accurately. they can be mimiced by many non neoplastic conditions of skin. so discussing both T and B cell lymphomas
Microsatellite instability testing is an important part in diagnostics in Metastatic cancer settings after the FDA has given approval for tissue agnostic indications in almost all solid cancers. MSI by PCR and MMR status by IHC is also helpful for evaluation of genetic risk in Colon and Endometrial cancers
various cutaneous lymphomas though having low incidence but need to be diagnosed accurately. they can be mimiced by many non neoplastic conditions of skin. so discussing both T and B cell lymphomas
Microsatellite instability testing is an important part in diagnostics in Metastatic cancer settings after the FDA has given approval for tissue agnostic indications in almost all solid cancers. MSI by PCR and MMR status by IHC is also helpful for evaluation of genetic risk in Colon and Endometrial cancers
In the recent years, knowledge about cancer biomarkers has increased tremendously
providing great opportunities for improving the management of cancer patients by
enhancing the efficiency of detection and efficacy of treatment.
• Recent technological advancement has enabled the examination of many
potential biomarkers and renewed interest in developing new biomarkers.
• Biomarkers of cancer could include a broad range of biochemical entities, such as nucleic
acids, proteins, sugars, lipids, and small metabolites, cytogenetic and cytokinetic
parameters as well as whole tumour cells found in the body
fluid. A COMPREHENSIVE UNDERSTANDING OF THE RELEVANCE
OF EACH BIOMARKER WILL BE VERY IMPORTANT NOT
ONLY FOR DIAGNOSING THE DISEASE RELIABLY, BUT ALSO
HELP IN THE CHOICE OF MULTIPLE THERAPEUTIC
ALTERNATIVES CURRENTLY AVAILABLE THAT IS LIKELY TO
BENEFIT THE PATIENTS.• Measure or evaluate the normal biological process, pathogenic processes, or
pharmacological response to a therapeutic interventions.
• Includes ~ diagnostic test and imaging technology
• “ Cancer is clusters disease involving alterations in status and expression of
multiple genes that confer a survival advantage & diminished proliferative
potential to somatic or germinal cells"
Specific to tumor
• Level change in response to tumor size
• No fluctuations in level
• Low level in healthy individual
• Predict recurrence
• Test should be cost effective
DNA methylation
2. Alteration pattern of histone modification
3. Alterations in chromatin condensation
In the recent years, knowledge about cancer biomarkers has increased tremendously
providing great opportunities for improving the management of cancer patients by
enhancing the efficiency of detection and efficacy of treatment.
• Recent technological advancement has enabled the examination of many
potential biomarkers and renewed interest in developing new biomarkers.
• Biomarkers of cancer could include a broad range of biochemical entities, such as nucleic
acids, proteins, sugars, lipids, and small metabolites, cytogenetic and cytokinetic
parameters as well as whole tumour cells found in the body
fluid. A COMPREHENSIVE UNDERSTANDING OF THE RELEVANCE
OF EACH BIOMARKER WILL BE VERY IMPORTANT NOT
ONLY FOR DIAGNOSING THE DISEASE RELIABLY, BUT ALSO
HELP IN THE CHOICE OF MULTIPLE THERAPEUTIC
ALTERNATIVES CURRENTLY AVAILABLE THAT IS LIKELY TO
BENEFIT THE PATIENTS.• Measure or evaluate the normal biological process, pathogenic processes, or
pharmacological response to a therapeutic interventions.
• Includes ~ diagnostic test and imaging technology
• “ Cancer is clusters disease involving alterations in status and expression of
multiple genes that confer a survival advantage & diminished proliferative
potential to somatic or germinal cells"
Specific to tumor
• Level change in response to tumor size
• No fluctuations in level
• Low level in healthy individual
• Predict recurrence
• Test should be cost effective
DNA methylation
2. Alteration pattern of histone modification
3. Alterations in chromatin condensation
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
1. High Ki67 expression is an independent
good prognostic marker in colorectal
cancer
Nathaniel Melling, Charlotte Marie Kowitz, Ronald Simon, Carsten Bokemeyer,
Luigi Terraciano, Guido Sauter, Jakob Robert Izbicki, Andreas Holger Marx
J Clin Pathol August 2016;69:209-214
Presenter : Dr.Revathi Krishnamurthy
Moderator : Dr.K.K.Suresh
2. INTRODUCTION
• Colorectal carcinomas vary considerably throughout the
world, being one of the leading cancer sites in the developed
countries
• Adenocarcinoma of the colon is the most common
malignancy of the gastrointestinal (GI) tract
3. EPIDEMIOLOGY
• Colorectal adenocarcinoma is responsible for nearly 10% of
all cancer deaths worldwide
• Incidence : Age : 60 to 70 years
• Sex : Males and females are affected equally
4. ETIOLOGY
Diet and lifestyle
• Low intake of vegetable fibre
• High intake of refined carbohydrates & fat
• Risk factors : Meat consumption, smoking & alcohol
consumption
5. Chronic inflammation
Ulcerative colitis
Premalignant
disorder
Risk of developing
carcinoma is up to
20-fold
Crohn Disease
Risk of developing
carcinoma appears to
be 3 fold above
normal
6. Modifying factors
• Non-steroidal anti-inflammatory drugs & some naturally
occurring compounds block the biochemical abnormalities in
prostaglandin homeostasis in colorectal neoplasms
• Cause a dramatic involution of adenomas
• But their role in the chemoprevention of adenocarcinoma is
less clear
7. Localisation :
• Most commonly : - Sigmoid colon
- Rectum
• In recent years, there is evidence of changing distribution
with an increasing proportion of more proximal carcinomas
8. Clinical features
Proximal colon Distal colon
• Polypoid, exophytic masses • “Napkin-ring” constriction
• Rarely cause obstruction • Cause obstruction
• Fatigue & weakness • Occult bleeding, changes in
bowel habits or left lower
quadrant discomfort
13. CEA
• Adenocarcinoma Equally distributed throughout the
cell surface
• Normal mucosa Polar distribution
Reactivity for CEA is also the rule
14. CDX2
• Found in majority of colorectal carcinomas
• Also expressed in : Primary mucin-producing carcinomas of
- Ovary
- Bladder
- Lung
- Pancreaticobiliary adenocarcinomas
15. Tumour associated glycoprotein (TAG-72)
• Invasive colorectal adenocarcinoma
• Hyperplastic & adenomatous polyps
• Normal mucosa
• Frequency of reactivity and the pattern of expression vary
depending on the condition
17. Other markers consistently expressed by colorectal carcinoma
regardless of differentiation are :
• Cathepsin B
• Neuropilin-1
• SRCA2
• Cadherin-17
18. • Uncontrolled proliferation is a hallmark of malignancy
• This can be assessed by various methods, the simplest is a
count of the mitotic figures in stained tissue sections
• The most widely practiced measurement involves the
immunohistochemical (IHC) assessment of Ki67 antigen
19. Ki67
• Huge protein of approximately 395 kDa
• Encoded for by almost 30,000 base pairs within the human
genome
• Originally identified by a German group in the early 1980s, by
use of a mouse monoclonal antibody against a nuclear antigen
from a Hodgkin's lymphoma-derived cell line
• Ki Kiel University, Germany
• 67 label clone number on the 96-well plate
20. • Undergoes phosphorylation and dephosphorylation during
mitosis
• Susceptible to proteases
• Its structure implies that its expression is regulated by
proteolytic pathways
• Shares structural similarities with other proteins known to be
involved in cell cycle regulation
• It has a very complex and specific localization pattern within
the nucleus, one which changes during the cell cycle
21. • The expression of Ki67 protein is strictly associated with cell
proliferation
• Interphase Nucleus
• Mitosis Surface
• All active phases of the cell cycle
(G(1), S, G(2), and mitosis)
• Absent from resting cells (G(0))
Excellent marker for
determining the growth
fraction of a given cell
population
22. Function of Ki67
• Vital for cell proliferation, since removal of Ki67 using
antisense nucleotides prevents cell proliferation
• This protein is tightly controlled and regulated, implying a
fundamental function in cell proliferation
23. p53 : (Guardian of the genome)
Exposure of cells to radiation or chemotherapeutic agents
Induces apoptosis by a mechanism that is initiated by DNA
damage
P53 accumulates in the cells when DNA is damaged
Arrests cell cycle Triggers apoptosis
24. Mutated or absent p53
• p53 serves as a critical “life or death” switch following
genotoxic stress
Neoplastic transformation
Cells with damaged DNA fail to undergo p53
mediated apoptosis & survive
25. WNT signalling pathway
• Major role in controlling cell fate, adhesion, and cell polarity
during embryonic development
• Signals through a family of cell surface receptors called
frizzled (FRZ)
• Stimulates several pathways, the central one involving
- ß-catenin
- APC Holds ß catenin
activity in check
26. Absence of WNT signalling
APC causes the formation
of macromolecular
‘destruction’ complex
Degradation of β catenin
WNT signalling
Blocks formation of
destruction complex
Stabilisation of β catenin
Translocates to nucleus &
forms activation complex
with DNA binding factor TCF
Promotes growth of colonic
epithelial cells
28. INTRODUCTION
• Colorectal cancer (CRC) is the fourth most common
malignant disease with over one million novel cases and
over 500 000 deaths each year worldwide
• Although recent advances in the management of the disease
have improved outcomes, CRC remains the second leading
cause of cancer-related death in Western countries
• In advanced metastatic CRC, surgery alone is not curative,
and therefore, adjuvant chemotherapy is needed
29. • Patients with nodal negative disease generally show a
favourable clinical course
• However, approximately one-third of node negative CRCs
recur or show progressive disease, suggesting failure to
detect occult disease
• Because aberrant genetic changes occur early in tumour
progression, molecular profiling of specific tumour markers
in the primary tumour might predict the tumour’s metastatic
potential
30. • Thus, patients with a potentially aggressive tumour, although
not yet metastasised at the time of surgery, might also benefit
from adjuvant therapy
31. Ki67 :
• It is a nuclear antigen
• Expressed in proliferating cells from G1 to M-phase of the
cell cycle
• Many studies have shown a predictive role of Ki67 in a wide
range of human malignancies :
- Gastrointestinal stromal tumours
- Gastro-intestinal neuroendocrine tumours
- Prostate cancer
- Breast cancer
32. Ki67 Labelling Index : (Ki67LI)
• The quantification of Ki67 expression by immunohistochemistry
is known as the Ki67 labelling index
• It is the percentage of invasive cancer cell nuclei that are positive
for Ki67 immunostaining over total invasive cancer cell nuclei
present in a histological sample
• It has become a routine practice in clinical pathology to estimate
the growth fraction of a tumour
33. • For example, in hormone-positive breast cancer, Ki67 is
currently used to predict the efficacy of pure hormone
receptor blockade without chemotherapy in the neoadjuvant
setting
• In well differentiated neuroendocrine tumours (NETs), Ki67
staining of core biopsies of the primary usually provides a
reliable method of proliferation assessment for prognosis of
metastatic NETs to the liver
• Only few studies exist on the prognostic role of Ki67 in
CRC, and have partially shown contradictory results
34. Immunohistochemical study
Large cohort of patients with
CRC using pre-existing CRC
microarray
1800 CRC specimens
- Clinical follow-up
- Extensive molecular data
35. • The results of this study show that high Ki67 expression is
an independent predictor of favourable outcome in CRC
• Thus, patients with CRC that show low Ki67LI may benefit
from adjuvant therapy
36. Patients and Tissue Microarray Construction
• Two different tissue microarrays (TMAs) with a total of
1800 CRC samples were included in this study
37. First TMA
Institute of Pathology of the
University Hospital of Basel
1420 patients
• Raw survival data were obtained
from the responsible physicians
for all of the 1420 patients
• The median follow-up time was
46 months
Operated between
1988 and 1996
38. Second TMA
380 patients
Institute of Pathology of the
University Medical Centre,
Hamburg-Eppendorf
Operated between
1993 to 2006
• Raw survival data were
available for all of the 380
patients
• The median follow-up period
of 36 months
39. • Neoadjuvant therapy - None
• Postoperative therapy – Guidelines for treatment of CRC
• For both cohorts, no clinical data were available regarding
the state of disease progression, no separation of patient
population based on RECIST guidelies
40. • For TMA construction, H&E-stained sections were made
from each block to define representative tumour regions
• Tissue cylinders with a diameter of 0.6 mm were then
punched from tumour areas of each ‘donor’ tissue block
using a home-made semi-automated precision instrument
and brought into empty recipient paraffin blocks
• Four-micrometre sections of the resulting TMA blocks were
transferred to an adhesive-coated slide system
41. Patient information and clinical data such as :
• Age
• Sex
• Localisation
• Type of the tumour
• Pathological tumour-node-metastases stage
• Carcinoma grade
Retrospectively retrieved from clinical and pathological
databases
42. • All tumours were reclassified by two pathologists
Follow-up data :
• Local cancer register boards
• Attending physicians
43. • For statistical analyses, tumour localisations were grouped as
follows:
• Right-sided cancer (caecum, ascending colon, transverse
colon)
• Left-sided cancer (splenic flexure, descending colon,
sigmoid colon and rectum)
44. Ki67 Immunohistochemistry :
• Standard indirect immunoperoxidase procedures were used
for the detection of Ki67
• Sections were heated in an autoclave at 121°C for 10 min in
citrate buffer ( pH 9.0)
• Chromogen - Diaminobenzidine
• Counterstain - Mayer’s haematoxylin
• Only unequivocal nuclear staining, regardless of its
intensity, was counted
45. • For statistical analyses, the staining results were
categorised into three groups (weak, moderate, high)
according to the percentage of Ki67-positive tumour
cells as follows:
Category % of Ki-67 positive
tumour cells
Low 0 - 10
Moderate 10 - 25
High >25
47. Technical issues :
• A total of 1653 (91.8%) tumour samples were interpretable
in this TMA analysis
• Reasons for non-informative cases (147 spots, 8.2%)
included :
1. Lack of tissue samples or
2. Absence of unequivocal cancer tissue in the TMA
spot
48. Ki67 expression in CRC
Low
26.30%
Moderate
56.7%
High
17%
Low Moderate High
50. Using Ki67 as a continuous variable , Ki67 expression was :
Associated with : Not associated with :
• Low tumour stage and
nodal status
• Tumour grade
• Histological tumour type
• Tumour localistaion
51. Association with β-catenin and p53 expression
• Strong immunohistochemical positivity for
p53 - 41.5%
ß-catenin - 75.8%
• Significantly associated with left-sided tumour localisation
52.
53. Survival analysis
High tumour stage and grade as well as advanced nodal status
were associated with poor patient survival
54. Survival analysis
Left sided CRCs were associated with a better prognosis as
compared with tumours of the right side and transverse colon
56. • Histological tumour type was unrelated to clinical outcome
• Immunohistochemical p53 and ß-catenin status of the CRC
did not show any impact on survival
57.
58. DISCUSSION
• The results of this study show that in CRC, high Ki67
expression is an independent favourable prognostic marker
• This finding is comparable with previous results
59. Study by Salminen et al :
• Analysing 146 patients who had CRC with rectal and
rectosigmoid cancer
High proliferative activity
measured by Ki67
Survival improvement
compared with patients
with low Ki67
60. Study by Reimers et al :
• 285 patients with stage I–IV colon cancer
• Ki67 and cleaved caspase-3 tumour expression were used to
develop the combined apoptosis proliferation parameter and
to correlate the results to patient outcome
• Patients with high levels of both apoptosis and proliferation
showed the best outcome perspectives
61. Palmqvist et al :
Low Ki67 index at the
invasive tumour margin
Poor prognosis in
Duke’s Stage B CRC
62. In contrast, in many other tumour types, including endocrine
tumours, gastrointestinal stromal tumour, head and neck,
prostate and breast cancer, high Ki67 index has been linked to
poor outcome
The reason for this discrepancy between the impact of Ki67
expression on prognosis in CRC and a wide range of other
human malignancies is unclear
63. Duchrow et al :
• Compared the expression of Ki67 mRNA and protein in
CRC
Minimum of one-third of CRCs
- High Ki67 protein level
- Low mRNA expression
Proliferate more slowly
than expected
Grow more slowly than
indicated by Ki67LI
Significant number of
non-cycling tumour cells
express Ki67
64. Ki67-positive non-cycling tumour cells
More stable than tumour cells that cannot achieve cell cycle
arrest
More resistant to adjuvant therapies or patient’s immune
response
65. • Interestingly, in oestrogen receptor-positive breast cancer,
Ki67 expression was suggested to identify a subset of
cancers, which may be sensitive to docetaxel treatment in the
adjuvant setting
• Ki67 determination has also been suggested as a tool in
selecting patients with rectal cancer for radiotherapy
66. • In routine clinical practice, core biopsies from the tumour or
metastases are usually taken to assess the molecular
characteristics of their malignancy
• The question remains, whether the Ki67LI obtained from a
core needle biopsy adequately represents the whole tumour
or metastases
67. • A study using TMAs of hepatic metastases from well-
differentiated NETs demonstrated good correlation between
Ki67LI in 1–3 random core biopsies and whole sections of
G1 tumours in nearly 100% and in about 50% of G2 tumours
• Thus, the authors concluded that a single needle core biopsy
randomly taken from within a tumour or metastasis usually
provides adequate proliferation assessment, despite the
presence of intratumoral heterogeneity
• Therefore, it can be assumed that Ki67 expression analysis
using TMAs constructed from one 0.6 mm core per patient
yields representative results comparable with random core
needle biopsies
68. Limitations of the study
• The proliferative activity is often heterogeneous within a
tumour
• Best area for assessment of Ki67LI :
• Can be accomplished by using whole section slides
Zone of high
proliferation
Invasive margin of
the tumour
69. Limitations of the study
• The cut-off levels of Ki67 expression used in this study are
currently being applied in breast cancer diagnostics, and
have been shown to be reproducible and significant
• However, a standardised method of Ki67 assessment is
needed for other tumour types, including CRC
70. • As expected, Ki67-h was strongly linked to high nuclear ß-
catenin and p53 expression in this cohort
• This observation fits well with the known relationship of
p53, ß-catenin and Ki67 in cell proliferation
• ß-Catenin is a key factor of Wingless Int-1 (WNT)
signalling, and nuclear translocation of ß-catenin
characterises cells with active WNT signalling
• Active WNT signalling leads to enhanced cell proliferation
and, thus, to elevated Ki67LI
71. • Mutated p53 accumulates in tumour cells, and thus, serves as
a marker of high proliferative activity too
72. • Besides factors that influence cell proliferation, biomarker
that plays a critical role in regulating epithelial–
mesenchymal transition (EMT) in cancer cells has recently
been evaluated for clinical significance
• Toiyama et al have shown that increased expression of slug
and vimentin, which play a critical role in regulating EMT
via downregulation of epithelial markers and upregulation of
mesenchymal markers, is significantly associated with poor
prognosis
73. • Another study by Satelli et al has suggested that detecting
and measuring cell-surface vimentin on the surface of EMT-
circulating tumour cells from blood of patients may predict
progressive disease in CRC
• However, the relationship between EMT-regulating factors
and cell proliferation needs to be further elucidated
74. Take home message
High Ki67 expression in CRCs is associated with good
clinical outcome
Ki67, p53 and ß-catenin overexpression seem to be linked
to CRC, and indicate a cellular state of high proliferative
activity
The findings strongly argue for a clinical utility of Ki67
immunostaining as an independent prognostic biomarker in
CRC that may contribute to the prognostic evaluation in
patients with CRC
75.
76. 1 Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin
2011;61:69–90.
2 Bilchik AJ, Nora DT, Saha S, et al. The use of molecular profiling of early
colorectal cancer to predict micrometastases. Arch Surg 2002;137:1377–83.
3 Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody
specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a
subset of normal lymphoid cells. Nature 1982;299:65–7.
4 de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in
early breast cancer: a meta-analysis of published studies involving 12,155
patients. Br J Cancer 2007;96:1504–13.
5 Jones RL, Salter J, A’Hern R, et al. The prognostic significance of Ki67 before
and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat
2009;116:53–68.
6 Zhao WY, Xu J, Wang M, et al. Prognostic value of Ki67 index in
gastrointestinal stromal tumors. Int J Clin Exp Pathol 2014;7:2298–304.
7 Yamaguchi T, Fujimori T, Tomita S, et al. Clinical validation of the
gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010
classification is appropriate to predict metastasis or recurrence. Diagn Pathol
2013;8:65.
REFERENCES
77. 8 Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of
distant metastasis and mortality for men with prostate cancer treated with
radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group
Trial 92-02. J Clin Oncol 2004;22:2133–40.
9 Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell
proliferationassociated human nuclear antigen defined by the monoclonal
antibody Ki-67. J Immunol 1984;133:1710–15.
10 Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis
of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736–50.
11 Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast
cancer: recommendations from the International Ki67 in Breast Cancer
working group. J Natl Cancer Inst 2011;103:1656–64.
12 Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the
assessment of Ki67 labeling index in well-differentiated neuroendocrine
tumors metastatic to the liver: implications for prognostic stratification. Am J
Surg Pathol 2011;35:853–60.
13 Porschen R, Lohe B, Hengels KJ, et al. Assessment of cell proliferation in
colorectal carcinomas using the monoclonal antibody Ki-67. Correlation with
pathohistologic criteria and influence of irradiation. Cancer 1989;64:2501–5.
14 Salminen E, Palmu S, Vahlberg T, et al. Increased proliferation activity
measured by immunoreactive Ki67 is associated with survival improvement in
rectal/recto sigmoid cancer. World J Gastroenterol 2005;11:3245–9.
78. 15 Reimers MS, Zeestraten EC, van Alphen TC, et al. Combined analysis of
biomarkers of proliferation and apoptosis in colon cancer: an
immunohistochemistry-based study using tissue microarray. Int J Colorectal Dis
2014;29:1043–52.
16 Palmqvist R, Sellberg P, Oberg A, et al. Low tumour cell proliferation at the
invasive margin is associated with a poor prognosis in Dukes’ stage B colorectal
cancers. Br J Cancer 1999;79:577–81.
17 Schmiegel W, Pox C, Reinacher-Schick A, et al. S3 guidelines for colorectal
carcinoma: results of an evidence-based consensus conference on February 6/7,
2004 and June 8/9, 2007 ( for the topics IV, VI and VII). Z Gastroenterol
2010;48:65–136.
18 Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-
throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844–7.
19 Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on
proximal or distal tumor location. Ann Intern Med 1990;113:779–88.
20 von Wasielewski R, Klopper K, Luck HJ, et al. Improvement of breast cancer
grading in punch biopsies: grading with the Ki-67 marker. Pathologe 2006;27:337–
45.
21 Stuart-Harris R, Caldas C, Pinder SE, et al. Proliferation markers and survival in
early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825
patients. Breast 2008;17:323–34.
79. 22 Nishimukai A, Yagi T, Yanai A, et al. High Ki-67 expression and low
progesterone receptor expression could independently lead to a worse
prognosis for postmenopausal patients with estrogen receptor-positive
and HER2-negative breast cancer. Clin Breast Cancer 2015;15:204–11.
23 La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning
pancreatic endocrine tumours. Virchows Arch 1996;429:323–33.
24 Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas:
Ki-67 immunoreactivity on paraffin sections is an independent predictor
for malignancy: a comparative study with proliferating-cell nuclear antigen
and progesterone receptor protein immunostaining, mitotic index, and
other clinicopathologic variables. Hum Pathol 1996;27:1124–34.
Incidence peaks at 60-70 yr of age with fewer than 20% occurring before age 50
Thus underlying cause of iron deficiency anemia in an older man or postmenopausal woman is GI cancer unless proven otherwise
Colorectal adenocarcinomas are invariably positive for cytokeratins
The most common pattern exhibited is
Imp for D/D btwn colorectal adenocarcinoma & adenocarcinoma of other sites (lung,ovary)
Failure to demonstrate CEA makes colorectal origin unlikely
Elevated serum CEA levels >5ng/ml have adverse effect on prognosis independent of tumour stage
Lymph node metastasis from a colon cancer demonstrating strong immunoreactivity for carcinoembryonic antigen
Encodes a transcription factor that plays an important role in the proliferation and differentiation of intestinal epithelial cells
However it is not specific
But reactivity is less intense and patchy in others
In 100% colorectal adenocarcinoma
Cat -(a lysosomal cysteine ;proteinase
Neur - a molecule normally present in the developing nervous system
SRCA2- an ATPase crucial to many cell fucntions
This non-histone protein was named after the researchers' location,
Forkhead associated domain
Interphase, the antigen can be exclusively detected within the nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes
Exact role is still obscure and less published information on its overall function
Arrests cell cycle giving it time for repair
Hwever if the damage is too great to be repired successfully, p53 triggers apoptosis
Degradation of Bcatenin – preventing its accumulation in the cytoplasm
To further elucidate the clinical relevance of Ki67 as a prognostic tumour marker,
Resection specimens of 1420 speicmens of CRC
Operated at the dept of surgery of University hospital of Basel
Second tma included samples from 380 patients with CRC whose tumour resection specimens were examined at Institute of
This Ki67 labelling index is also currently being applied in grading breast cnacer
Ki67 expression was significantly related to nuclear ß-catenin and p53 expression
As expected, high tumour stage and grade as well as advanced nodal status were associated with poor patient survival while histological tumour type was unrelated to the clinicl outcome
In a multivariable cox proportional hazards regression model for survival only tumour stage,nodal status & Ki67IHC retained significance
However,can be acc by using whol section slides where the invasive margin of the tumour is clearly visible